FDA approves Keytruda as adjuvant treatment for kidney cancer

fda approves keytruda as adjuvant treatment for kidney cancer

Sumary of FDA approves Keytruda as adjuvant treatment for kidney cancer:

  • The approval followed results of the pivotal Phase 3 KEYNOTE-564 trial study, in which Keytruda showed a significant reduction in the risk of disease recurrence or death by 32 percent compared to placebo.
  • (iStock) Dr. Toni K. Choueiri, primary investigator of the study and director of the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, told Fox News that doctors have tried for decades to experiment with immunotherapy as a way to decrease recurrence in kidney cancer.
  • The phase 3 study involved multiple clinical sites, and was a randomized, double-blind placebo controlled trial that investigated the use of Keytruda as adjuvant therapy in 994 patients with intermediate-high or high risk of recurrence of RCC or M1 no evidence of disease (NED).
  • According to the recently published study in the New England Journal of Medicine, 496 patients were randomly assigned to receive pembrolizumab and 498 received a placebo.
  • The authors of the study found that pembrolizumab therapy was associated with significantly longer disease-free survival than placebo.
  • The study found at the 24-month follow-up, a 77.3 percent disease free survival in the KEYTRUDA group vs 68.1 percent in the placebo group.
  • BIDEN’S CLAIM THAT ‘DOGS MAY HELP CURE CANCER’ DRAWS TWITTER REACTIONSNick Pannone, a 62-year-old Cape Cod resident, participated in the KEYNOTE-564 clinical trial and told Fox news he was diagnosed with renal cell carcinoma three years ago and treated for prostate cancer six years ago.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.